Publicações de Carlos Gustavo WAMBIER (50)

Commentary on picosecond Nd:YAG laser therapy for pigmentation due to lichen planus pigmentosus in a patient with skin of color.

May, 2024

Ler mais

JAAD case reports

Comparative Long-Term Efficacy of Phenol-Croton Oil Chemical Peels for Persistent Melasma at Varied Croton tiglium Oil Concentrations.

Apr, 2024

Ler mais

Journal of the American Academy of Dermatology

Minoxidil sulfotransferase enzymatical activity in plants: A novel paradigm in increasing minoxidil response in androgenetic alopecia.

Jan, 2024

Minoxidil is the only US FDA approved topical drug for the treatment of androgenetic alopecia (AGA). Minoxidil is effective in hair re-growth in 30%-40% of patients and 50% of males. To exert its hair growing effect, minoxidil must be sulfonated in the scalp by the minoxidil sulfotransferase enzyme (SULT1A1). Low scalp SULT1A1 correlates with lack of minoxidil response; thus, supplementing the scalp SULT1A1 with naturally occurring minoxidil sulfotransferase enzymes could potentially improve treatment outcomes in AGA patients. Ler mais

Journal of cosmetic dermatology Carregar mais  

Mitigation of risk of botulinum toxin A-induced blepharoptosis with hyperconcentrated glabellar injections.

Dec, 2023

Ler mais

Journal of the American Academy of Dermatology

Skin of color repigmentation after phenol-croton oil chemical peel.

Nov, 2023

Ler mais

Journal of the American Academy of Dermatology

Evaluation of hair regrowth after minoxidil and dutasteride tattooing in men with androgenetic alopecia.

Sep, 2023

Ler mais

JAAD international

Safer 1064 nm long-pulse frequency settings and safety eyewear setup to improve visualization of superficial veins.

Aug, 2023

Ler mais

Journal of the American Academy of Dermatology

Updates on level of evidence of clinical efficacy of facial phenol-croton oil peels and comments on history and mechanisms of action.

Jul, 2023

Ler mais

International journal of dermatology

Phenol-Croton Oil Chemical Peeling Induces Durable Improvement of Constitutional Periorbital Dark Circles.

Apr, 2023

Constitutional periorbital dark circles (PDC) are common in skin of color and represent a therapeutic challenge. Ler mais

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

About the pathways to deliver brimonidine to the Muller's muscle.

Mar, 2023

Ler mais

JAAD case reports

The effects of 35% trichloroacetic acid-Croton oil and 35% glycolic acid-Croton oil compared to 35% phenol-Croton oil Hetter's very heavy formula for deep chemical peel.

Nov, 2022

Ler mais

Journal of the American Academy of Dermatology

Impact of the COVID-19 pandemic on dermatology residency education in the United States: A cross-sectional survey.

Sep, 2022

Ler mais

JAAD international

Circulation, sensation, and hair growth: A reply.

Aug, 2022

Ler mais

Journal of the American Academy of Dermatology

Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients.

Jun, 2022

Ler mais

European urology

Reply to early-onset effluvium secondary to COVID-19 and body hair effluvium.

May, 2022

Ler mais

Journal of the American Academy of Dermatology

Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: Results from a randomized double-blinded placebo-controlled interventional study.

Apr, 2022

Atopic dermatitis (AD) is a common and chronic inflammatory skin disease that erupts periodically. Although the negative impact of the disorder on overall quality of life has been well established, new treatments for AD are still needed. Various studies have reported on cannabidiol's effectiveness in relieving pain and easing inflammation while not presenting major health risks. Ler mais

Journal of cosmetic dermatology

SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study.

Mar, 2022

Ler mais

Annals of thyroid

Trichloroacetic acid peels for the treatment of acanthosis nigricans.

Jan, 2022

Ler mais

Journal of the American Academy of Dermatology

Scalp neuropathy in androgenetic alopecia.

Jan, 2022

Ler mais

Journal of the American Academy of Dermatology

Electrocardiogram Findings in Patients with Alopecia Areata.

Dec, 2021

While autoimmune comorbidities are common in alopecia areata, little is known about comorbid cardiovascular disease. The purpose of this study was to evaluate the incidence of bradyarrhythmia in patients with alopecia areata. Ler mais

Dermatology and therapy

Response to "Microneedling with autologous platelet-rich plasma versus microneedling with topical insulin in the treatment of postacne atrophic scars: A simultaneous split-face comparative study".

Dec, 2021

Ler mais

Journal of the American Academy of Dermatology

Influence of climate factors on pediatric alopecia areata flares in Philadelphia, Pennsylvania.

Oct, 2021

Patients with alopecia areata (AA) may experience episodic disease flares characterized by increasing hair loss that follow a seasonal pattern. However, no studies have examined whether specific climate factors contribute to the seasonal pattern of AA flares. Using Spearman rank correlation analyses, we assessed the association between climate variables and AA flare frequency per month in 336 children with AA in Philadelphia, Pennsylvania. Region-specific monthly values for average ambient temperature, air pressure, cloudiness, hours of sunlight, relative humidity, number of days with sun, number of days with rain, volume of precipitation, wind gust, wind speed, and UV index from January 2015 to December 2017 were obtained from World Weather Online. We found significant (P < 0.05) correlations between AA flare frequency and UV index (R = - 0.66), precipitation (R = - 0.66), number of days with rain (R = - 0.70), number of days with sun (R = 0.62), and air pressure (R = 0.80). Stratified analyses showed even stronger associations with UV index and precipitation in patients with an atopic comorbidity. New significant correlations appeared with temperature, wind speed, and UV index of the prior month. However, in patients who did not have atopic comorbidities, we generally observed weaker and non-significant correlations between climate and AA flare frequency. This study suggests that certain climate factors may mediate the seasonal pattern of AA flares and may contribute to AA pathogenesis. Atopic AA patients may be more susceptible to the influence of climate compared to those with no history of atopy. Ler mais

Scientific reports

Time of onset and duration of post-COVID-19 acute telogen effluvium.

Oct, 2021

Ler mais

Journal of the American Academy of Dermatology

Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients.

Sep, 2021

In a prospective observational study (pre-AndroCoV Trial), the use of nitazoxanide, ivermectin and hydroxychloroquine demonstrated unexpected improvements in COVID-19 outcomes when compared to untreated patients. The apparent yet likely positive results raised ethical concerns on the employment of further full placebo controlled studies in early-stage COVID-19. The present analysis aimed to elucidate, through a comparative analysis with two control groups, whether full placebo-control randomized clinical trials (RCTs) on early-stage COVID-19 are still ethically acceptable. The Active group (AG) consisted of patients enrolled in the Pre-AndroCoV-Trial (n = 585). Control Group 1 (CG1) consisted of a retrospectively obtained group of untreated patients of the same population (n = 137), and Control Group 2 (CG2) resulted from a precise prediction of clinical outcomes based on a thorough and structured review of indexed articles and official statements. Patients were matched for sex, age, comorbidities and disease severity at baseline. Compared to CG1 and CG2, AG showed reduction of 31.5-36.5% in viral shedding (p < 0.0001), 70-85% in disease duration (p < 0.0001), and 100% in respiratory complications, hospitalization, mechanical ventilation, deaths and post-COVID manifestations (p < 0.0001 for all). For every 1000 confirmed cases for COVID-19, at least 70 hospitalizations, 50 mechanical ventilations and five deaths were prevented. Benefits from the combination of early COVID-19 detection and early pharmacological approaches were consistent and overwhelming when compared to untreated groups, which, together with the well-established safety profile of the drug combinations tested in the Pre-AndroCoV Trial, precluded our study from continuing employing full placebo in early COVID-19. Ler mais

New microbes and new infections

Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.

Sep, 2021

Ler mais

The Journal of urology

Characterization of the Activity of Croton tiglium Oil in Hetter's Very Heavy Phenol-Croton Oil Chemical Peels.

Jul, 2021

Croton oil (CO) is used by dermatologists and plastic surgeons in deep chemical peels. It is mixed with phenol, water, and a soap in Baker-Gordon's or Hetter's formulas. There is controversy as to whether CO or phenol is the active agent in the dermal effect of deep chemical peels. Ler mais

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Letter to the Editor re: Baldassarri et al., 2021 "Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males".

Jun, 2021

Ler mais

EBioMedicine

Letter to the Editor on "COVID-19 Infection in Men on Testosterone Replacement Therapy".

Jun, 2021

Ler mais

The journal of sexual medicine

5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia.

Apr, 2021

Ler mais

Journal of the European Academy of Dermatology and Venereology : JEADV

Lucio's Phenomenon.

Apr, 2021

Ler mais

The New England journal of medicine

Reply to comment on: The Gabrin sign.

Mar, 2021

Ler mais

Journal of the American Academy of Dermatology

Translational research on the role of formula stability in Hetter's phenol-croton oil peels: Analysis of chemical studies and clinical outcomes from a randomized, double-blinded, split-face controlled trial.

Mar, 2021

Ler mais

Journal of the American Academy of Dermatology

Could diet and exercise reduce risk of COVID-19 syndemic?

Mar, 2021

We present a hypothesis for increased sugar consumption and a lack of physical exercise as possible determinants of COVID-19 disease severity by impaired glucose metabolism, concurring into a syndemic. National data demonstrate that increased sugar consumption, a high daily caloric intake, and low levels of daily physical activity are independently associated with COVID-19 mortality. Further, genetic factors such as variations in the androgen receptor may compound the effects of an unhealthy lifestyle and increase the risk of severe COVID-19 symptoms in some patients. A diet high in sugar in combination with a low level of physical activity may increase blood glucose levels and impair glucose metabolism. Recent data show that patients admitted to the hospital with high levels of fasting blood glucose are at an increased risk for severe COVID-19 symptoms. Moreover, elevated glucose levels resulted in increased SARS-CoV-2 viral loads in vitro. We believe that healthier habits of diet and exercise, by improving glucose homeostasis could modulate the individual risk of severe COVID-19 symptoms. Ler mais

Medical hypotheses

Clinical symptoms of hyperandrogenic women diagnosed with COVID-19.

Feb, 2021

Ler mais

Journal of the European Academy of Dermatology and Venereology : JEADV

Potential risk for developing severe COVID-19 disease among anabolic steroid users.

Feb, 2021

A severe case of COVID-19 was observed in an otherwise healthy 28-year-old man who had taken oxandrolone 40 mg/day as an anabolic steroid. The patient had been taking oxandrolone for enhanced bodybuilding 30 days prior to presenting to an outpatient clinic with COVID-19 symptoms. The patient reported that his symptoms have rapidly worsened over the course of 4 days prior to presenting at the clinic. As part of an experimental antiandrogen treatment for hyperandrogenic men suffering from COVID-19, he was administered a single 600 mg dose of the novel antiandrogen proxalutamide. Twenty-four hours after administration of this dose, marked improvement of symptoms and markers of disease severity were observed. To our knowledge, this is the first case that potentially links anabolic steroid use to COVID-19 disease severity. Ler mais

BMJ case reports

Reply to: "Comment on 'Androgenetic alopecia present in the majority of patients hospitalized with COVID-19'".

Jan, 2021

Ler mais

Journal of the American Academy of Dermatology

Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men.

Jan, 2021

Ler mais

Journal of the European Academy of Dermatology and Venereology : JEADV

Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients.

Jan, 2021

Ler mais

Journal of the European Academy of Dermatology and Venereology : JEADV

Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".

Jan, 2021

Ler mais

International journal of antimicrobial agents

Spironolactone in adolescent acne vulgaris.

Jan, 2021

Acne vulgaris (AV) is the most common skin condition affecting adolescents, most likely due to elevated androgen levels during puberty. Androgens stimulate and enlarge the sebaceous glands and keratinocytes, resulting in increased production of sebum and abnormal hyperproliferation of keratinocytes which lead to the formation of acne lesions. Current standard of care for AV includes topical therapies for mild cases and antibiotics or oral retinoids for severe cases. In recent years, spironolactone, an aldosterone antagonist and diuretic, has been applied to the treatment of AV due to its anti-androgen effects. Spironolactone is currently recommended in women who use oral contraceptives, are refractory to or contraindicated for standard treatment, show clinical signs of hyperandrogenism, or present with late-onset or persistent-recurrent AV past the teenage years. It is not prescribed to adolescents due to potential side effects; however, current data studying adults indicate that most side effects are mild, and that potential associations with hyperkalemia and increased risk of cancer are not sufficiently supported. Hence, we believe that spironolactone may be a safe and effective therapy for adolescent AV. Ler mais

Dermatologic therapy

Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster.

Jan, 2021

Ler mais

Medical hypotheses

Environmental Effects on Reported Infections and Death Rates of COVID-19 Across 91 Major Brazilian Cities.

Dec, 2020

Ler mais

High altitude medicine & biology

Male balding as a major risk factor for severe COVID-19: A possible role for targeting androgens and transmembrane protease serine 2 to protect vulnerable individuals.

Dec, 2020

Ler mais

Journal of the American Academy of Dermatology

Are night shift workers at an increased risk for COVID-19?

Nov, 2020

Recent data has revealed an association between coronavirus disease-19 (COVID-19) incidence and seasonally regulated androgen sensitivity. This potential relationship between SARS-CoV-2 infection and clock genes, coupled with previously reported effects of night shift work on health, leads us to hypothesize that night shift workers may be at an increased physiological risk of coronavirus disease-19 (COVID-19). Shift work, especially night shift work, has long been associated with several chronic health conditions. The mechanisms that drive these associations are not well understood; however, current literature suggests that the disruption of circadian rhythms may cause downstream hormonal and immune effects that render night shift workers more susceptible to disease. First, circadian rhythms may play a role in the mechanism of viral infection, as viral vaccines administered in the morning elicit greater immune responses than those administered in the afternoon. Next, increased exposure to light at night may inhibit the production of melatonin, which has been observed to enhance DNA repair and shown to upregulate expression of Bmal1, an established inhibitor of herpes simplex virus and influenza. Finally, abnormal immune cell and cytokine levels have been observed following night-shift work. These data suggest that further research is warranted and that high-risk occupations should be taken into consideration as public health policies are introduced and evolve. Ler mais

Medical hypotheses

Pernio during the COVID-19 pandemic and review of inflammation patterns and mechanisms of hypercoagulability.

Sep, 2020

Ler mais

JAAD case reports

Novel cannabidiol sunscreen protects keratinocytes and melanocytes against ultraviolet B radiation.

Sep, 2020

Cannabidiol (CBD), a natural occurring phytocannabinoid, is used extensively in consumer products ranging from foods to shampoos, topical oils and lotions. Several studies demonstrated the anti-inflammatory and antioxidative properties of cannabidiol. Nevertheless, the role of cannabidiol use in sunscreens is largely unknown as no studies on its effect on keratinocytes or melanocytes exist. As such, we aimed to explore the effect of CBD on keratinocyte and melanocyte viability following ultraviolet B (UVB) irradiation. CBD exhibited a dose-dependent protective effect on both keratinocytes and melanocyte viability. Further, since CBD does not demonstrate absorption in the UVB spectra, we speculate that the protective effect is due to reduction in reactive oxygen species. To our knowledge, this is the first study demonstrating the protective effect of CBD on keratinocytes and melanocytes irradiated with UVB. Ler mais

Journal of cosmetic dermatology

An Analysis of Information Sources of YouTube Videos Pertaining to Tattoo Removal: Cross-Sectional Study.

2022

The American Academy of Dermatology and the Food and Drug Administration recommend consultation with a dermatologist prior to undergoing laser tattoo removal. However, non-health care professionals offer tattoo removal. Understanding the information available on the internet for patients regarding tattoo removal is important given that individuals are increasingly consulting digital sources to make decisions regarding skin care. Prior research has identified that YouTube contains misinformation on dermatologic health. Ler mais

JMIR dermatology

Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil.

2022

P.1 lineage (Gamma) was first described in the State of Amazonas, northern Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of SARS-CoV-2 worldwide. P.1 has been linked to increased infectivity, higher mortality, and immune evasion, leading to reinfections and potentially reduced efficacy of vaccines and neutralizing antibodies. Ler mais

Frontiers in medicine

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial.

2021

Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale <3) were administered proxalutamide 200 mg/day or placebo for up to 7 days. The primary endpoint was hospitalization rate at 30 days post-randomization. A total of 268 men were randomized in a 1:1 ratio. 134 patients receiving proxalutamide and 134 receiving placebo were included in the intention-to-treat analysis. The 30-day hospitalization rate was 2.2% in men taking proxalutamide compared to 26% in placebo, < 0.001. The 30-day hospitalization risk ratio was 0.09; 95% confidence interval (CI) 0.03-0.27. Patients in the proxalutamide arm more frequently reported gastrointestinal adverse events, however, no patient discontinued treatment. In placebo group, 6 patients were lost during follow-up, and 2 patients died from acute respiratory distress syndrome. Here we demonstrate the hospitalization rate in proxalutamide treated men was reduced by 91% compared to usual care. Ler mais

Frontiers in medicine

Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19.

2020

Ler mais

Frontiers in medicine